The Stahl Lab
The central goal of our research is to make profound impacts on our understanding and treatment of common metabolic diseases through continuous innovation. Our research approaches thrive at the interface of disciplines such as biology, chemistry, and bioengineering and are driven by a highly collaborative team science approach.
_JPG.jpg)
The Stahl laboratory is pioneering investigations into the role of biomechanical forces in brown adipose tissue (BAT) activation and developing innovative lipid nanoparticle-based strategies to expand and activate BAT. In parallel, the lab is advancing New Approach Methodologies (NAMs) through the development of human induced pluripotent stem cell (hiPSC)-derived microphysiological systems (MPS), or organ-on-a-chip platforms, designed to functionally interrogate the fat–liver axis. These human-relevant preclinical models are being leveraged to study fundamental biological processes, including aging, as well as metabolic diseases such as type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD). The platform also enables the evaluation of pharmacological interventions and therapeutic strategies in a physiologically relevant human context.
Multi-Organ system. The Stahl Lab utilizes microphysiological systems (MPS) based on PDMS platforms to model and investigate the interactions between multiple tissue types. These systems have been used to study a variety of tissues and cell types, including adipose tissue, liver, immune cells, and endothelial cells, enabling the investigation of complex multicellular interactions in a physiologically relevant microenvironment.
Microphysiological Systems
